Results from the Phase III RELIEF Trial and a Phase II Trial of Ruxolitinib in Patients with Polycythemia Vera or Essential Thrombocythemia


Results from the Phase III RELIEF Trial and a Phase II Trial of Ruxolitinib in Patients with Polycythemia Vera or Essential Thrombocythemia
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/14/15)
Mesa R et al. The efficacy and safety of continued hydroxyurea therapy versus switching to ruxolitinib in patients with polycythemia vera: A randomized, double-blind, double-dummy, symptom study (RELIEF). Proc ASH 2014;Abstract 3168.

Verstovsek S et al. Long-term results from a phase II open-label study of ruxolitinib in patients with essential thrombocythemia refractory to or intolerant of hydroxyurea. Proc ASH 2014;Abstract 1847.

Dr Cortes is DB Lane Cancer Research Distinguished Professor for Leukemia Research and Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.